April 25, 2023 08:30 ET | Source: Orgenesis Inc.
GERMANTOWN, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announces Vered Caplan, CEO of Orgenesis, has been invited to participate in a keynote series, ‘applied continuous and modular manufacturing innovations,’ where she plans to discuss the latest innovations at the Company’s POCare Services subsidiary, Morgenesis, LLC, including its Orgenesis Mobile Processing Units and Labs (OMPULs), which provide decentralized autologous cell and gene therapies to patients at lower costs.
The keynote series will be delivered at the INTERPHEX conference. This event covers the pharmaceutical product development lifecycle, between April 25-27, 2023, at the Javits Centre in New York. The Keynote Series will be held on the Innovation Stage, Booth #1378 on Wednesday, Apr 26, between 1:15 pm and 3:00 pm Eastern Time.
The keynote series will cover how the bio and pharma industries can build on the successes of continuous manufacturing (CM) for the advanced manufacture of pharmaceuticals. These successes have included buy-in and support from regulatory authorities, including the FDA.
About Orgenesis
Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform and OMPUL business, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, our ability to manage potential disruptions as a result of the COVID-19 pandemic, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our POCare strategy, our trans differentiation technology as therapeutic treatment for diabetes, the technology behind our in-licensed ATMPs not functioning as expected, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.
IR contact for Orgenesis:
Crescendo Communications, LLC
Tel: 212-671-1021
Orgs@crescendo-ir.com
Communications contact for Orgenesis:
IB Communications
orgenesis@ibcomms.agency
Tel +44 (0)20 8943 4685
https://www.globenewswire.com/news-release/2023/04/25/2653903/24226/en/Orgenesis-CEO-Vered-Caplan-Featured-in-Keynote-Series-at-INTERPHEX-Conference-to-Discuss-Innovations-in-Cell-Gene-Therapy-Manufacturing.html
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Recent ORGS News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 12:30:47 PM
- Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia • GlobeNewswire Inc. • 08/29/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:05:13 PM
- Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally • GlobeNewswire Inc. • 08/14/2024 12:30:00 PM
- Orgenesis Provides Second Quarter 2024 Business Update • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2024 03:25:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/14/2024 12:45:29 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/14/2024 04:15:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:05:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/06/2024 08:05:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 10:14:05 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/24/2024 01:16:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:00:31 PM
- Orgenesis Provides Business Update for the First Quarter of 2024 • GlobeNewswire Inc. • 05/21/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 08:01:42 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 08:01:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 07:28:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/06/2024 07:26:43 PM
- Orgenesis Provides Year End Business Update • GlobeNewswire Inc. • 04/15/2024 09:07:16 PM
- Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility • GlobeNewswire Inc. • 04/10/2024 04:00:00 PM
- Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference • GlobeNewswire Inc. • 03/18/2024 12:30:00 PM
- Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes • GlobeNewswire Inc. • 03/13/2024 12:30:00 PM
- Orgenesis Inc. Announces $2.3 Million Private Placement • GlobeNewswire Inc. • 03/04/2024 01:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM